review punch scotti pt
report financi updat brief investor
busi preclin anim early-stag human data provid
regul reassur project good
potenti given get go-ahead start phase
soon potenti start earli summer potenti vaccin
approv could happen truli warp speed drug develop
project import valuat cmv cancer vaccin etc also continu
briskli testament compani mrna platform manufactur scale
invest inform technolog lead edg preclin clinic talent
took decad develop updat model increas pt
focu call perhap clearest signal
fast develop path recent comment dr fauci niaid
strong immun respons seen anim model fda clearanc go
phase phase could start earli summer initi select
dose phase trial hv placebo control
almost warp speed develop start
prepar phase protocol start summer caution best
plan outcom howev believ recent fast-mov success
cmv vaccin scalabl platform safeti particip /efficaci
profil vaccin eight vaccin demonstr neutral antibodi
increas po
coupl key issu give us extra convict updat
pt firstli agreement lonza plan run ex-u
trial could mean ww right like kept
secondli on-going discuss regulatori bodi world-wide could
result quicker approv assum approv ex-u
scale develop capabl develop
project continu cmv studi fulli enrol interim readout
slate particip begin
host clinic initi readout expect next month
slide broaden platform potenti
point investor decade-long invest ip
manufactur inform technolog combin world-beat
preclin clinic mrna platform potenti perfectli posit
respond pandem need vaccin speed
scale frankli astonish histor measur much
done stay bullish
found pioneer
new class medicin made
technolog platform transform
bodi cell drug-subst
technolog solut rapid
scale mrna approach
perhap unmatch histori drug
analyst certif import disclosur see disclosur
year price histori
estim peak revenu potenti initi develop
program rang
estim need rais excess approxim
billion reach commerci
assum first product on-market earlier approv
upsid model
given product develop clinic typic
biotech approv probabl early-stag suggest
achiev minimum product approv current
approv would constitut upsid model
price conserv end biolog
focu reduc biolog develop risk
would constitut signific upsid model
compani stage develop
pre-approv valuat focus potenti futur
revenu stream po platform-multipl approach
base expect launch first
product next year estim total revenu
could reach billion time-frame frame
refer antibodi pioneer genentech herceptin/rituxan/
avastin current constitut total ww
first interim analysi phase dose-
confirm studi cmv
data phase safeti immunogen data readout
first cohort phase initi phase
initi earli summer
phase studi protocol phase
cmv initi
acknowledg possibl signific downsid
estim due inher risk drug develop
worst case stock could littl valu
calcul diseas portfolio-specif revenu potenti assess sum-of-the-part risk-adjust valuat compani
ascrib revenu multipl base develop program potenti expand platform area discount
wacc includ cash billion arriv equiti valu billion per share
believ success next sever year highli depend posit clinic data fda approv launch
current experiment clinic compound biggest risk product candid failur gain fda approv therefor
becom commerci product gain approv risk remain includ manufactur secur favor reimburs
price patient behavior physician adopt product patent protect structur chang healthcar market
modalityprogramprogram indicationtimingmilestoneprophylact syncyti viru rsv rsv phase safeti immunogen data syncyti viru rsv vaccinewil move plan phase studi time due lower potenc base preclin cmv interim analysi phase dose-confirm studi cmv phase plan cmv metapneumoviru parainfluenza viru enrol paus due seroposit age de-escal immunogen data vaccineadvanc subject vaccineadvanc subject develop plan follow posit phase interim viru ebv rsv file phase safeti immunogen data readout first cohort phase vaccineadvanc subject fundingcanc cancer vaccin clinic data led cancer vaccin on-going phase kra cancer vaccin merck studyintratumor solid tumors/lymphoma advanc ovarian carcinoma ph dose phase advanc ovarian carcinoma triplet solid dose escal initi dose disease-specif solid phase studi mrna encod inject intratumorallyloc regen myocardi cardiac function data random phase studysystem secret chikungunya enrol paus due data addit cohort heart file fabri fabri ind filingsystem intracellular methylmalon acidemia enrol paus due proof concept biomark phase propion acidemia enrol paus due pa enrol pa phase i/ii phenylketonuria pku ind glycogen storag disord type ind file moderna inc
statement million except per product revenu relat good expens paid repurchas redeem redeem convert prefer unit redempt stock incom avail common per pro forma share per share dilut pro forma share dilut share inc
exhibit inform guidanc
exhibit manufactur collabor lonza
stock price compani mention report
